By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Noven Pharmaceuticals Inc. 

11960 S.W. 144th Street

Miami  Florida  33186-5807  U.S.A.
Phone: 305-253-5099 Fax:


Company News
Noven Pharmaceuticals Inc. Release: New Minivelle (Estradiol Transdermal System) 0.025 mg/day Dose Now Available by Prescription in U.S. Pharmacies 2/12/2015 7:30:15 AM
Noven Pharmaceuticals Inc. Files Patent Infringement Lawsuit Against Actavis (ACT) 10/17/2014 10:44:35 AM
Noven Pharmaceuticals Inc. Announces Publication Of Exploratory Analyses From Pooled Phase 3 Results Of The Effects Of BrisdelleĀ® (Paroxetine) Capsules On Weight And Sexual Function During Treatment Of Vasomotor Symptoms Associated With Menopause 10/14/2014 8:23:42 AM
Noven Pharmaceuticals Inc. Receives FDA Approval Of A New Indication With A New Dose For MinivelleĀ® (Estradiol Transdermal System) 9/24/2014 11:12:58 AM
Noven Pharmaceuticals Inc. Appoints Krista Roberts As Vice President Of Operations 6/23/2014 8:50:55 AM
Pharma Firms Like Merck & Co., Inc. (MRK) And Noven Pharmaceuticals Inc. Flock To Miami 4/30/2014 8:16:07 AM
Noven Pharmaceuticals Inc. Announces Settlement Of Lidoderm® Patent Litigation 4/17/2014 9:55:46 AM
Noven Pharmaceuticals Inc. Enters Co-Promotion Agreement With Shionogi, Inc. For Brisdelle™ (Paroxetine) Capsules 1/13/2014 12:08:31 PM
Noven Pharmaceuticals Inc. Release: First and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Hot Flashes Now Available by Prescription in U.S. Pharmacies 11/5/2013 7:45:50 AM
Noven Pharmaceuticals Inc. Release: Data on Brisdelleā„¢ (Paroxetine) Capsules, the First and Only FDA-Approved Non-Hormonal Therapy for Moderate to Severe Vasomotor Symptoms Associated with Menopause, to be Presented at the 2013 Annual Meeting of The North American Menopause Society 10/2/2013 9:55:23 AM